copper peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-25. Numbers and descriptions here follow the published literature rather than marketing material.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II)-tripeptide complex | One peptide ligand with one coordinated metal centre |
| Peptide sequence | Gly-His-Lys | Three residues written in one-letter notation |
| Free peptide mass | 340.4 g/mol | Metal-free GHK; the complex has a higher mass |
| Appearance | Blue to violet solid or solution | Colour originates from copper d orbital transitions |
| Storage | Desiccated, -20 °C, protected from light | Dry powder is more stable than dissolved material |
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
As for snack food, the now popular tramezzini were first served in a historic café of downtown Turin, namely Caffè Mulassano, where they were devised in 1925 as an alternative to English tea sandwiches. In recent years, another trademark drink of the city is MoleCola, an Italian cola that entered production in 2012 and quickly spread both in Italy and outside its native country. Local cuisine also features a particular type of pizza, so-called pizza al padellino or pizza al tegamino, which is basically a small-sized, thick-crust and deep-dish pizza typically served in several Turin pizza places. Since the mid-1980s, Piedmont has also benefited from the start of the Slow Food movement and Terra Madre, events that have highlighted the rich agricultural and vinicultural value of the Po Valley and northern Italy.
=== 12 December === President Zelenskyy appealed to the G7 for tanks, artillery and long range weapons. In response, the G7 pledged to meet Ukraine's requirements. Luhansk's exiled Governor Serhiy Haidai claimed that Ukraine's armed forces killed personnel from the Wagner Group, a private military company in the Luhansk Region. The UK sanctioned Russian military commanders for missile attacks and Iranian businessmen for the production and supply of military drones. The EU sanctioned 20 individuals and one entity of Iran over human rights abuse. European Union Foreign Ministers claimed that they had evidence to support Iran supplying Shahed-136 drones to Russia despite denials from both countries.
Loss of E-cadherin is considered to be a fundamental event in EMT. Many transcription factors (TFs) that can repress E-cadherin directly or indirectly can be considered as EMT-TF (EMT inducing TFs). SNAI1/Snail 1, SNAI2/Snail 2 (also known as Slug), ZEB1, ZEB2, TCF3 and KLF8 (Kruppel-like factor 8) can bind to the E-cadherin promoter and repress its transcription, whereas factors such as Twist, Goosecoid, TCF4 (also known as E2.2), homeobox protein SIX1 and FOXC2 (fork-head box protein C2) repress E-cadherin indirectly. SNAIL and ZEB factors bind to E-box consensus sequences on the promoter region, while KLF8 binds to promoter through GT boxes. These EMT-TFs not only directly repress E-cadherin, but also repress transcriptionally other junctional proteins, including claudins and desmosomes, thus facilitating EMT. On the other hand, transcription factors such as grainyhead-like protein 2 homologue (GRHL2), and ETS-related transcription factors ELF3 and ELF5 are downregulated during EMT and are found to actively drive MET when overexpressed in mesenchymal cells. Since EMT in cancer progression recaptures EMT in developmental programs, many of the EMT-TFs are involved in promoting metastatic events. Several signaling pathways (TGF-β, FGF, EGF, HGF, Wnt/beta-catenin and Notch) and hypoxia may induce EMT. In particular, Ras-MAPK has been shown to activate Snail and Slug. Slug triggers the steps of desmosomal disruption, cell spreading, and partial separation at cell–cell borders, which comprise the first and necessary phase of the EMT process.
In general, polymeric mixtures are far less miscible than mixtures of small molecule materials. This effect results from the fact that the driving force for mixing is usually entropy, not interaction energy. In other words, miscible materials usually form a solution not because their interaction with each other is more favorable than their self-interaction, but because of an increase in entropy and hence free energy associated with increasing the amount of volume available to each component. This increase in entropy scales with the number of particles (or moles) being mixed. Since polymeric molecules are much larger and hence generally have much higher specific volumes than small molecules, the number of molecules involved in a polymeric mixture is far smaller than the number in a small molecule mixture of equal volume. The energetics of mixing, on the other hand, is comparable on a per volume basis for polymeric and small molecule mixtures. This tends to increase the free energy of mixing for polymer solutions and thereby making solvation less favorable, and thereby making the availability of concentrated solutions of polymers far rarer than those of small molecules. Furthermore, the phase behavior of polymer solutions and mixtures is more complex than that of small molecule mixtures.
Sources: en.wikipedia.org
Carpal Tunnel Syndrome Fact Sheet (National Institute of Neurological Disorders and Stroke) Archived 2016-03-03 at the Wayback Machine NHS website carpal-tunnel.net provides a free to use, validated, online self diagnosis questionnaire for CTS "Carpal Tunnel Syndrome". MedlinePlus. U.S. National Library of Medicine.
== S == Saegusa–Ito oxidation Sakurai reaction Salol reaction Sandheimer Sandmeyer diphenylurea isatin synthesis Sandmeyer isonitrosoacetanilide isatin synthesis Sandmeyer reaction Sanger reagent Saponification Sarett oxidation Schiemann reaction Schiff reaction Schiff test Schlenk equilibrium Schlosser modification Schlosser variant Schmidlin ketene synthesis Schmidt degradation Schmidt reaction Scholl reaction Schorigin Shorygin reaction, Shorygin reaction, Wanklyn reaction Schotten–Baumann reaction Seliwanoff's test Semidine rearrangement Semmler–Wolff reaction Seyferth–Gilbert homologation Shapiro reaction Sharpless asymmetric dihydroxylation Sharpless epoxidation Sharpless oxyamination or aminohydroxylation Shenck ene reaction Shi epoxidation Shiina esterification Shiina macrolactonization or Shiina lactonization Sigmatropic reaction Simmons–Smith reaction Simonini reaction Simonis chromone cyclization Simons process Skraup chinolin synthesis Skraup reaction Smiles rearrangement SNAr nucleophilic aromatic substitution SN1 SN2 SNi Solvolysis Sommelet reaction Sonn–Müller method Sonogashira coupling Sørensen formol titration Staedel–Rugheimer pyrazine synthesis Stahl oxidation Staudinger reaction Staudinger synthesis Steglich esterification Stephen aldehyde synthesis Stetter reaction Stevens rearrangement Stieglitz rearrangement Stille coupling Stobbe condensation Stollé synthesis Stork acylation Stork enamine alkylation Strecker amino acid synthesis Strecker degradation Strecker sulfite alkylation Strecker synthesis Stereocontrolled 1,2-addition to carbonyl groups Suzuki coupling Swain equation Swarts reaction Swern oxidation
=== Procedure (Micro Assay, 1-10 μg protein/mL) === Prepare standard concentrations of protein of 1, 5, 7.5 and 10 μg/mL. Prepare a blank of NaCl only. Prepare a series of sample dilutions. Add 100 μL of each of the above to separate tubes (use microcentrifuge tubes) and add 1.0 mL of Coomassie Blue to each tube. Turn on and adjust a spectrophotometer to a wavelength of 595 nm, and blank the spectrophotometer using 1.5 mL cuvettes or use a mobile smartphone camera (RGBradford method). Wait 2 minutes and read the absorbance of each standard and sample at 595 nm. Plot the absorbance of the standards vs. their concentration. Compute the extinction coefficient and calculate the concentrations of the unknown samples.
Sources: en.wikipedia.org
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.
The three letters are the standard one-letter codes for glycine, histidine, and lysine. The suffix -Cu indicates the coordinated copper ion. Cosmetic ingredient lists often use the alternative name copper tripeptide-1 for the same complex.
No. Free GHK is the peptide alone, while GHK-Cu contains a bound copper atom. The two differ in colour, charge, and binding behaviour, so any study that measures copper delivery must state which form was used.
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.